M&T Bank Corp Has $299,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

M&T Bank Corp reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.5% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,987 shares of the medical research company’s stock after selling 259 shares during the period. M&T Bank Corp’s holdings in Charles River Laboratories International were worth $299,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRL. Cibc World Markets Corp grew its holdings in Charles River Laboratories International by 16.1% during the fourth quarter. Cibc World Markets Corp now owns 8,086 shares of the medical research company’s stock valued at $1,493,000 after purchasing an additional 1,124 shares during the period. Royal London Asset Management Ltd. grew its stake in shares of Charles River Laboratories International by 6.4% in the fourth quarter. Royal London Asset Management Ltd. now owns 16,425 shares of the medical research company’s stock worth $3,032,000 after purchasing an additional 991 shares during the last quarter. Quantbot Technologies LP boosted its position in shares of Charles River Laboratories International by 13.8% in the 4th quarter. Quantbot Technologies LP now owns 9,300 shares of the medical research company’s stock worth $1,717,000 after purchasing an additional 1,131 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Charles River Laboratories International by 5.6% in the 4th quarter. American Century Companies Inc. now owns 2,984 shares of the medical research company’s stock worth $551,000 after purchasing an additional 157 shares in the last quarter. Finally, Sei Investments Co. lifted its position in Charles River Laboratories International by 6.1% in the 4th quarter. Sei Investments Co. now owns 673,868 shares of the medical research company’s stock valued at $124,394,000 after acquiring an additional 38,827 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president directly owned 19,513 shares of the company’s stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $156.86 on Friday. The company has a market capitalization of $7.70 billion, a PE ratio of -241.32, a price-to-earnings-growth ratio of 5.25 and a beta of 1.49. The firm has a fifty day simple moving average of $147.10 and a 200-day simple moving average of $151.02. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $254.15.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.27 earnings per share. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRL has been the subject of several recent analyst reports. Robert W. Baird upped their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a report on Thursday, May 8th. Barclays lifted their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 8th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their target price for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. TD Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 target price on the stock in a report on Wednesday, May 14th. Finally, Wall Street Zen lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, July 5th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International currently has an average rating of “Hold” and a consensus target price of $174.54.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).